Patrick Fitzsimmons
Pain Medicine · Slidell, LANPI 1215496484
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.2%), education and travel and lodging — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Nevro Corp. at 37.5% of the total. Reporting peaked in 2023 at $3,791 and has fallen 87.9% since, to $458 in 2025.
Across 51 payments — averaging $110.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$2K
- Boston Scientific$2K
- Medtronic$417
- Stryker$341
- Avanos Medical$273
- Curonix LLC$268
- plus $379 from 8 others
What the payments were for
- Travel & lodging$1,15020%
- Food & beverage$3,28658%
- Education$1,21421%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 11 | $2,116 |
| Boston Scientific | 15 | $1,855 |
| Medtronic | 7 | $417 |
| Stryker | 3 | $341 |
| Avanos Medical | 4 | $273 |
| Curonix LLC | 2 | $268 |
| Averitas Pharma Inc. | 1 | $122 |
| Merz Pharmaceuticals, LLC | 2 | $109 |
| Spinal Simplicity, LLC | 1 | $34 |
| Saluda Medical Americas, Inc. | 1 | $29 |
| AbbVie | 1 | $28 |
| SPR Therapeutics, Inc | 1 | $23 |
| Hydrocision, Inc. | 1 | $20 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,650 in reported general payments places this provider in the 60th percentile of 97 pain medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 16 | $181 |
| Baclofen | 12 | $155 |
| Oxycodone Hcl | 11 | $117 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Slidell
- Marianne GelterSlidell$4K
- John VuSlidell$4K
- Artemus FlaggSlidell$3K
- Thomas MyersMandeville$118K
- Alan KayeNew Orleans$76K
- Derrick DeanTerrytown$68K
- Hazem EissaNew Orleans$50K
- Robert OwensNew Orleans$47K
- Gassan ChaibanLake Charles$30K
- Yashar EshraghiNew Orleans$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.